China Biotech Services Holdings Limited (8037.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In HKD
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
141
First IPO Date
June 17, 2004
| Name | Title | Pay | Year Born |
| Ye Yin | Executive Director | 261,000 | 1979 |
| Xun He | Executive Director | 261,000 | 1964 |
| Song Huang | Chief Technology Officer & Executive Director | 600,000 | 1982 |
| Yi Yao | Consultant | 1.1M | 1959 |
| Xiaolin Liu | Executive Chairman & Compliance Officer | 5.25M | 1970 |
| Xuanming Yang | Chief Scientific Officer | 0 | N/A |
| Pui Yin Fung | Company Secretary | 0 | N/A |
Established in 1996 and based in Causeway Bay, Hong Kong, China Biotech Services Holdings Limited functions as an investment holding company. Its core business involves providing medical laboratory testing and health check services throughout mainland China and Hong Kong. The company organizes its varied operations into five main divisions: Immunotherapy, Pharmaceutical Products, Medical and Health Related Services, Securities, and Insurance Brokerage, in addition to other undertakings. Its comprehensive activities include the research, development, manufacturing, and sale of both health-related and pharmaceutical products. The company also offers specialized medical services, such as tumor immune cell therapy, immune cell storage, and health management programs, alongside coordinating healthcare providers. Furthermore, it participates in financial services like securities trading, money lending, and providing insurance brokerage. Its commercial ventures also extend to marketing and distributing a range of wellness products, including health supplements, slimming aids, traditional Chinese medicines, and beauty products, as well as trading pharmaceutical intermediates. Property investment and logistics services round out its operational scope. The company transitioned to its current name in November 2017, having previously been known as Rui Kang Pharmaceutical Group Investments Limited.